RecruitingNCT07017907

Evaluating an AI Tool for Detecting Thyrotoxic States

Performance Evaluation of the Software Medical Device to Detect the Thyrotoxic State in Patients With Hyperthyroidism


Sponsor

THYROSCOPE INC.

Enrollment

15 participants

Start Date

Jan 9, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This observational study aims to evaluate the performance of a software-based medical device, Glandy HYPER, in detecting the thyrotoxic state in patients with hyperthyroidism. The device utilizes heart rate data collected from commercially available wearable devices and compares it with thyroid function test results. The study will enroll patients diagnosed with Graves' disease, monitoring their heart rate during sleep and correlating these measurements with free T4 levels obtained through serial blood testing. No investigational device output will be disclosed to participants, and the study will not alter standard clinical care.


Eligibility

Min Age: 22 Years

Inclusion Criteria4

  • Adults aged 22 years or older, regardless of sex.
  • Individuals who are newly diagnosed with Graves' disease or currently undergoing treatment for it.
  • Individuals who have received sufficient explanation about the investigational software and are able to use it appropriately.
  • Individuals who voluntarily agree to participate in the study and have signed informed consent, either directly or via a legally authorized representative.

Exclusion Criteria6

  • Individuals with cardiac conditions such as arrhythmia or heart failure.
  • Individuals taking medications that significantly affect heart rate, including antiarrhythmics or antihistamines. (Intermittent short-acting beta-blockers are allowed.)
  • Pregnant or breastfeeding individuals, or those planning pregnancy during the study period or not using appropriate contraception.
  • Individuals with significant comorbidities that interfere with follow-up or study compliance.
  • Individuals with severe psychiatric disorders, substance use disorder, or alcohol dependence.
  • Individuals deemed ineligible at the discretion of the investigator for safety or ethical concerns.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEHeart rate-based AI software for detecting thyrotoxicosis

A software-based investigational medical device that uses artificial intelligence to detect the thyrotoxic state in patients with hyperthyroidism. The device analyzes resting heart rate data collected from wearable devices along with thyroid function test results (free T4 and TSH). The device is not FDA-approved and will be used solely for observational performance evaluation without influencing clinical care.


Locations(1)

Umesh Masharani

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07017907


Related Trials